Late Breaker: The CDC issued a new advisory last week regarding the use of nirsevimab due to the manufacturer releasing an additional 230,000 doses in January. CDC is now recommending a return to the original ACIP recommendations for use. Accordingly, a single dose of nirsevimab is recommended for all infants less than 8 months of age as well as for all children 8 to 19 months old who are at increased risk for severe disease. For more information please see: emergency.cdc.gov/newsletters/coca/2024/010524a.html and Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023 | MMWR (cdc.gov)